CA2372521C - Mixed-bed solid phase and its use in the isolation of nucleic acids - Google Patents
Mixed-bed solid phase and its use in the isolation of nucleic acids Download PDFInfo
- Publication number
- CA2372521C CA2372521C CA002372521A CA2372521A CA2372521C CA 2372521 C CA2372521 C CA 2372521C CA 002372521 A CA002372521 A CA 002372521A CA 2372521 A CA2372521 A CA 2372521A CA 2372521 C CA2372521 C CA 2372521C
- Authority
- CA
- Canada
- Prior art keywords
- solid phase
- mixed
- solution
- silica
- bed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007790 solid phase Substances 0.000 title claims abstract description 531
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 297
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 297
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 297
- 238000002955 isolation Methods 0.000 title description 44
- 239000000203 mixture Substances 0.000 claims abstract description 170
- 238000000034 method Methods 0.000 claims abstract description 123
- 239000013612 plasmid Substances 0.000 claims abstract description 95
- 239000000356 contaminant Substances 0.000 claims abstract description 69
- 239000012149 elution buffer Substances 0.000 claims abstract description 54
- 230000003321 amplification Effects 0.000 claims abstract description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 10
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 617
- 239000000377 silicon dioxide Substances 0.000 claims description 296
- 239000002245 particle Substances 0.000 claims description 226
- 239000006249 magnetic particle Substances 0.000 claims description 143
- 230000005291 magnetic effect Effects 0.000 claims description 106
- 239000000463 material Substances 0.000 claims description 58
- 238000005349 anion exchange Methods 0.000 claims description 50
- 239000002158 endotoxin Substances 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 42
- 238000005342 ion exchange Methods 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 230000003196 chaotropic effect Effects 0.000 claims description 30
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 28
- 238000005119 centrifugation Methods 0.000 claims description 15
- 229920000936 Agarose Polymers 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 10
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 10
- 150000001450 anions Chemical group 0.000 claims description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 229960001340 histamine Drugs 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- 238000010908 decantation Methods 0.000 claims description 2
- SGKDAFJDYSMACD-UHFFFAOYSA-N dimethoxy(propyl)silane Chemical compound CCC[SiH](OC)OC SGKDAFJDYSMACD-UHFFFAOYSA-N 0.000 claims description 2
- 230000005484 gravity Effects 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims 4
- 239000006167 equilibration buffer Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 238000010828 elution Methods 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 239000013611 chromosomal DNA Substances 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 280
- 108020004414 DNA Proteins 0.000 description 173
- 239000006166 lysate Substances 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 66
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 239000003480 eluent Substances 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 48
- 239000000523 sample Substances 0.000 description 44
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 42
- 239000000499 gel Substances 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- 239000011543 agarose gel Substances 0.000 description 22
- 238000009739 binding Methods 0.000 description 22
- 230000027455 binding Effects 0.000 description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 18
- 229960005542 ethidium bromide Drugs 0.000 description 17
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 238000000926 separation method Methods 0.000 description 15
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 13
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000011109 contamination Methods 0.000 description 11
- 125000000524 functional group Chemical group 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 229910052742 iron Inorganic materials 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000013068 control sample Substances 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- -1 lymph Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 6
- 238000002123 RNA extraction Methods 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108091006522 Anion exchangers Proteins 0.000 description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000007885 magnetic separation Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000002902 bimodal effect Effects 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- 238000007399 DNA isolation Methods 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108010072542 endotoxin binding proteins Proteins 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000000383 hazardous chemical Substances 0.000 description 3
- 238000009616 inductively coupled plasma Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000000696 magnetic material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000005372 silanol group Chemical group 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052723 transition metal Inorganic materials 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- ZLDHYRXZZNDOKU-UHFFFAOYSA-N n,n-diethyl-3-trimethoxysilylpropan-1-amine Chemical compound CCN(CC)CCC[Si](OC)(OC)OC ZLDHYRXZZNDOKU-UHFFFAOYSA-N 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000013077 target material Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 238000011050 LAL assay Methods 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- SAQSTQBVENFSKT-UHFFFAOYSA-M TCA-sodium Chemical compound [Na+].[O-]C(=O)C(Cl)(Cl)Cl SAQSTQBVENFSKT-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012629 conventional elemental analysis Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- SQNZJJAZBFDUTD-UHFFFAOYSA-N durene Chemical compound CC1=CC(C)=C(C)C=C1C SQNZJJAZBFDUTD-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000002902 ferrimagnetic material Substances 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000642 polymer Chemical class 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/20—Anion exchangers for chromatographic processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J47/00—Ion-exchange processes in general; Apparatus therefor
- B01J47/02—Column or bed processes
- B01J47/04—Mixed-bed processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/312,139 | 1999-05-14 | ||
| US09/312,139 US6270970B1 (en) | 1999-05-14 | 1999-05-14 | Mixed-bed solid phase and its use in the isolation of nucleic acids |
| PCT/US2000/012954 WO2000070041A1 (en) | 1999-05-14 | 2000-05-12 | Mixed-bed solid phase and its use in the isolation of nucleic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2372521A1 CA2372521A1 (en) | 2000-11-23 |
| CA2372521C true CA2372521C (en) | 2009-09-08 |
Family
ID=23210049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002372521A Expired - Fee Related CA2372521C (en) | 1999-05-14 | 2000-05-12 | Mixed-bed solid phase and its use in the isolation of nucleic acids |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6270970B1 (enExample) |
| EP (1) | EP1179056B1 (enExample) |
| JP (1) | JP2002543980A (enExample) |
| AT (1) | ATE272111T1 (enExample) |
| AU (1) | AU774810B2 (enExample) |
| CA (1) | CA2372521C (enExample) |
| DE (1) | DE60012506T2 (enExample) |
| WO (1) | WO2000070041A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425138D0 (en) | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
| US6914137B2 (en) * | 1997-12-06 | 2005-07-05 | Dna Research Innovations Limited | Isolation of nucleic acids |
| BR9815569A (pt) * | 1997-12-06 | 2001-10-09 | Dna Res Instr Ltd | Método para extração de biomoléculas de material biológico |
| US7078224B1 (en) | 1999-05-14 | 2006-07-18 | Promega Corporation | Cell concentration and lysate clearance using paramagnetic particles |
| AU2862100A (en) * | 1999-01-27 | 2000-08-18 | Folim G. Halaka | Materials and methods for the purification of polyelectrolytes |
| DE10013990C2 (de) * | 2000-03-22 | 2003-12-04 | Invitek Biotechnik & Biodesign | Polyfunktionelles Trägermaterial für die komplexe Nukleinsäureanalytik |
| US20030087286A1 (en) * | 2000-09-06 | 2003-05-08 | Hodge Timothy A. | Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles |
| US7011943B2 (en) * | 2000-09-06 | 2006-03-14 | Transnetyx, Inc. | Method for detecting a designated genetic sequence in murine genomic DNA |
| US20050266494A1 (en) * | 2000-09-06 | 2005-12-01 | Hodge Timothy A | System and method for computer network ordering of biological testing |
| US20030082605A1 (en) * | 2000-09-06 | 2003-05-01 | Hodge Timothy A. | Genomic DNA detection method and system thereof |
| US7494817B2 (en) * | 2000-09-06 | 2009-02-24 | Transnet Yx, Inc. | Methods for genotype screening using magnetic particles |
| US20050239125A1 (en) * | 2000-09-06 | 2005-10-27 | Hodge Timothy A | Methods for genotype screening |
| US20050272085A1 (en) * | 2000-09-06 | 2005-12-08 | Hodge Timothy A | Methods for forensic and congenic screening |
| US20030207289A1 (en) * | 2001-09-04 | 2003-11-06 | Hodge Timothy A. | Detection of genetic sequences using a bipartite probe |
| ES2273915T3 (es) * | 2000-11-13 | 2007-05-16 | Promega Corporation | Depuracion de lisado y aislamiento de acido nucleico utilizando matrices de silica silanizadas. |
| CA2433746A1 (en) * | 2001-01-09 | 2002-07-18 | Whitehead Institute For Biomedical Research | Methods and reagents for the isolation of nucleic acids |
| US20060014186A1 (en) * | 2001-09-04 | 2006-01-19 | Hodge Timothy A | Methods for genotype screening of a strain disposed on an adsorbent carrier |
| US20050032105A1 (en) * | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
| US7148343B2 (en) * | 2001-10-12 | 2006-12-12 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
| US7893228B2 (en) * | 2001-10-12 | 2011-02-22 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify RNA |
| WO2003046146A2 (en) * | 2001-11-28 | 2003-06-05 | Applera Corporation | Compositions and methods of selective nucleic acid isolation |
| US6833238B2 (en) | 2002-01-04 | 2004-12-21 | Applera Corporation | Petal-array support for use with microplates |
| CA2473376A1 (en) | 2002-01-16 | 2003-07-31 | Dynal Biotech Asa | Method for isolating nucleic acids and protein from a single sample |
| GB0207975D0 (en) * | 2002-04-05 | 2002-05-15 | Genovision As | Isolating nucleic acid |
| GB0209382D0 (en) * | 2002-04-24 | 2002-06-05 | Genovision As | Isolating nucleic acid |
| US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| US20040016702A1 (en) * | 2002-07-26 | 2004-01-29 | Applera Corporation | Device and method for purification of nucleic acids |
| US20060160085A1 (en) * | 2002-11-08 | 2006-07-20 | Timo Hillebrand | Novel buffer formulations for isolating purifying and recovering long-chain and short-chain nucleic acids |
| AU2004205671A1 (en) * | 2003-01-21 | 2004-08-05 | Perkinelmer Health Sciences, Inc. | Method and system for microfluidic manipulation, amplification and analysis of fluids, for example, bacteria assays and antiglobulin testing |
| CN1764842B (zh) * | 2003-03-24 | 2012-01-11 | 索尼株式会社 | 微芯片、用于提取核酸的试剂盒以及核酸的提取方法 |
| US20040197780A1 (en) * | 2003-04-02 | 2004-10-07 | Agencourt Bioscience Corporation | Method for isolating nucleic acids |
| US20050026153A1 (en) * | 2003-07-31 | 2005-02-03 | Iannotti Claudia A. | Devices and methods for isolating RNA |
| US20050042660A1 (en) * | 2003-07-31 | 2005-02-24 | Hall Gerald Edward | Devices and methods for isolating RNA |
| EP1508618B1 (en) * | 2003-08-19 | 2012-07-25 | Kurashiki Boseki Kabushiki Kaisha | Extracting apparatus |
| US20050106577A1 (en) * | 2003-11-17 | 2005-05-19 | Hashem Akhavan-Tafti | Cleavable solid phases for isolating nucleic acids |
| US20050106576A1 (en) * | 2003-11-17 | 2005-05-19 | Hashem Akhavan-Tafti | Methods of using cleavable solid phases for isolating nucleic acids |
| US20060160122A1 (en) * | 2004-02-18 | 2006-07-20 | Applera Corporation | Polyelectrolyte-coated size-exclusion ion-exchange particles |
| US20050196856A1 (en) * | 2004-02-18 | 2005-09-08 | Applera Corporation | Polyelectrolyte-coated size-exclusion ion-exchange particles |
| US20050181378A1 (en) * | 2004-02-18 | 2005-08-18 | Applera Corporation | Polyelectrolyte-coated size-exclusion ion-exchange particles |
| SE0400490D0 (sv) * | 2004-02-26 | 2004-02-26 | Amersham Biosciences Ab | Plasmid purification |
| JP4476050B2 (ja) * | 2004-06-30 | 2010-06-09 | 株式会社ニデック | 視野計 |
| CA2575140A1 (en) * | 2004-07-30 | 2006-02-09 | Agencourt Bioscience Corporation | Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers |
| US20060099605A1 (en) * | 2004-11-11 | 2006-05-11 | Hall Gerald E Jr | Devices and methods for isolating RNA |
| AU2005305012C1 (en) | 2004-11-05 | 2012-07-19 | Qiagen North American Holdings, Inc. | Compositions and methods for purifying nucleic acids from stabilization reagents |
| EP1693108A1 (en) * | 2004-12-04 | 2006-08-23 | MERCK PATENT GmbH | Mixed-modal anion-exchange type separation material |
| US20060223072A1 (en) * | 2005-03-31 | 2006-10-05 | Boyes Barry E | Methods of using a DNase I-like enzyme |
| US20060223073A1 (en) * | 2005-03-31 | 2006-10-05 | Boyes Barry E | Methods of using a DNase I-like enzyme |
| US20060234251A1 (en) * | 2005-04-19 | 2006-10-19 | Lumigen, Inc. | Methods of enhancing isolation of RNA from biological samples |
| US20060270843A1 (en) * | 2005-05-26 | 2006-11-30 | Hall Gerald E Jr | Methods for isolation of nucleic acids |
| US20060269929A1 (en) * | 2005-05-26 | 2006-11-30 | Hall Gerald E Jr | Methods and kits for DNA purification on polymeric membranes at low ionic strength |
| CA2613094A1 (en) * | 2005-07-01 | 2007-01-11 | Promega Corporation | Network of buoyant particles for biomolecule purification |
| DE102005047736B4 (de) * | 2005-09-29 | 2008-08-14 | Aj Innuscreen Gmbh | Verfahren und System zur Isolierung von Nukleinsäuren aus beliebigen komplexen Ausgangsmaterialien |
| EP1963526A4 (en) * | 2005-12-09 | 2009-11-18 | Promega Corp | PURIFICATION OF NUCLEIC ACID WITH A BINDING MATRIX |
| US20070190526A1 (en) * | 2006-02-16 | 2007-08-16 | Nexgen Diagnostics Llc | Methods of extracting nucleic acids |
| CA2668818C (en) | 2006-10-10 | 2018-06-26 | Xenomics, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
| JP2010515917A (ja) * | 2007-01-10 | 2010-05-13 | ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー | クロマトグラフィーレジン |
| US8308940B2 (en) | 2007-12-06 | 2012-11-13 | The Board Of Trustees Of The University Of Illinois | Chromatography devices and methods |
| JP5540467B2 (ja) * | 2008-01-21 | 2014-07-02 | Ｊｎｃ株式会社 | 上限臨界溶液温度を有する温度応答性ポリマーで表面修飾された磁性微粒子による電荷物質の回収方法及びキット |
| EP2347254A2 (en) | 2008-09-16 | 2011-07-27 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
| KR101569832B1 (ko) * | 2008-11-19 | 2015-11-18 | 삼성전자주식회사 | 시료 중의 게놈 ｄｎａ 및 플라스미드 ｄｎａ를 서로 분리하는 방법 및 그를 위한 키트 |
| US20100305219A1 (en) * | 2009-06-02 | 2010-12-02 | The Board Of Trustees Of The University Of Illinois | Emulsions and foams using patchy particles |
| US8039613B2 (en) | 2009-08-28 | 2011-10-18 | Promega Corporation | Methods of purifying a nucleic acid and formulation and kit for use in performing such methods |
| US8222397B2 (en) * | 2009-08-28 | 2012-07-17 | Promega Corporation | Methods of optimal purification of nucleic acids and kit for use in performing such methods |
| SG10201803960SA (en) | 2010-07-30 | 2018-07-30 | Emd Millipore Corp | Chromatography media and method |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EP2721140B1 (en) | 2011-06-19 | 2016-11-23 | Abogen, Inc. | Devices, solutions and methods for sample collection |
| JP6096774B2 (ja) * | 2011-08-12 | 2017-03-15 | キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 核酸を単離するための方法 |
| JP5899731B2 (ja) * | 2011-09-13 | 2016-04-06 | ソニー株式会社 | 核酸精製方法、核酸抽出方法、及び核酸精製用キット |
| CA2863215C (en) | 2012-01-30 | 2021-05-04 | Exact Sciences Corporation | Modification of dna on magnetic beads |
| JP6360482B2 (ja) | 2012-09-17 | 2018-07-18 | ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ | クロマトグラフィー担体及びデバイス |
| EP3578652B1 (en) | 2013-03-15 | 2023-07-12 | ModernaTX, Inc. | Ribonucleic acid purification |
| EP2983804A4 (en) * | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| WO2014144874A1 (en) | 2013-03-15 | 2014-09-18 | Avellino Lab Usa, Inc. | Methods for improved isolation of genomic dna templates for allele detection |
| WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| DK3019619T3 (da) | 2013-07-11 | 2021-10-11 | Modernatx Inc | Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder |
| AU2014305085A1 (en) * | 2013-08-05 | 2016-02-25 | The Johns Hopkins University | Fabrication of hierarchical silica nanomembranes and uses thereof for solid phase extraction of nucleic acids |
| US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
| EP3872192A1 (en) | 2013-11-15 | 2021-09-01 | Avellino Lab USA, Inc. | Methods for multiplex detection of alleles associated with ophthalmic conditions |
| SG11201607364RA (en) * | 2014-03-07 | 2016-10-28 | Dna Genotek Inc | Composition and method for stabilizing nucleic acids in biological samples |
| US11389783B2 (en) | 2014-05-02 | 2022-07-19 | W.R. Grace & Co.-Conn. | Functionalized support material and methods of making and using functionalized support material |
| US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
| EP3169335B8 (en) | 2014-07-16 | 2019-10-09 | ModernaTX, Inc. | Circular polynucleotides |
| CN107001410A (zh) | 2014-12-08 | 2017-08-01 | Emd密理博公司 | 混合床离子交换吸附剂 |
| US9422596B1 (en) * | 2015-04-27 | 2016-08-23 | Norgen Biotek Corp. | Methods and columns for nucleic acid purification |
| CN107921407B (zh) | 2015-06-05 | 2022-07-05 | 格雷斯公司 | 生物处理吸附澄清剂及其制备和使用方法 |
| WO2017049275A2 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a stabilizing tail region |
| US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
| KR20180120670A (ko) | 2015-11-13 | 2018-11-06 | 아벨리노 랩 유에스에이, 인크. | 각막 이상증의 치료 방법 |
| WO2017193097A1 (en) | 2016-05-06 | 2017-11-09 | Girihlet Inc. | Methods and compositions for determining specifc tcr and bcr chain pairings |
| WO2017223176A1 (en) | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Methods and apparatus for filtration |
| CA3061620A1 (en) | 2017-04-28 | 2018-11-01 | Avellino Lab Usa, Inc. | Methods for detecting alleles associated with keratoconus |
| EP3630971A1 (en) * | 2017-05-22 | 2020-04-08 | QIAGEN Healthcare Biotechnologies Systems Limited | Improvements in the recovery of nucleic acids from solid supports |
| EP3762491B1 (en) | 2018-03-03 | 2023-09-20 | Labcyte Inc. | Method for extracting a target moiety from a sample using acoustic droplet ejection |
| PL3663401T3 (pl) * | 2019-02-28 | 2023-02-27 | Lonza Ltd | Sposób oczyszczania cząsteczek biologicznych takich jak plazmidowy DNA przy zastosowaniu chromatografii anionowymiennej |
| CA3186515A1 (en) | 2020-07-29 | 2022-02-24 | Evan M. RAGLAND | Purification of sulfonated dna |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4233169A (en) | 1979-04-13 | 1980-11-11 | Corning Glass Works | Porous magnetic glass structure |
| US4297337A (en) | 1979-04-13 | 1981-10-27 | Corning Glass Works | Solid-phase immunoassays using magnetic glass |
| US4395271A (en) | 1979-04-13 | 1983-07-26 | Corning Glass Works | Method for making porous magnetic glass and crystal-containing structures |
| US4298500A (en) | 1980-05-05 | 1981-11-03 | Varian Associates, Inc. | Mixed phase chromatographic compositions |
| DE3211309A1 (de) | 1982-03-26 | 1983-09-29 | Metin Dipl.-Ing. 6100 Darmstadt Colpan | Chromatographisches verfahren zur isolierung von makromolekuelen |
| US4695393A (en) | 1983-05-12 | 1987-09-22 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
| US4672040A (en) | 1983-05-12 | 1987-06-09 | Advanced Magnetics, Inc. | Magnetic particles for use in separations |
| US4523996A (en) | 1984-02-22 | 1985-06-18 | Westinghouse Electric Corp. | Method of separating cationic from anionic beads in mixed resin beds |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5076950A (en) | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
| DE3639949A1 (de) | 1986-11-22 | 1988-06-09 | Diagen Inst Molekularbio | Verfahren zur trennung von langkettigen nukleinsaeuren |
| US4935342A (en) * | 1986-12-01 | 1990-06-19 | Syngene, Inc. | Method of isolating and purifying nucleic acids from biological samples |
| US4767670A (en) | 1987-01-21 | 1988-08-30 | E. I. Du Pont De Nemours And Company | Chromatographic supports for separation of oligonucleotides |
| US5075430A (en) | 1988-12-12 | 1991-12-24 | Bio-Rad Laboratories, Inc. | Process for the purification of DNA on diatomaceous earth |
| US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
| US5523231A (en) | 1990-02-13 | 1996-06-04 | Amersham International Plc | Method to isolate macromolecules using magnetically attractable beads which do not specifically bind the macromolecules |
| WO1992011933A1 (en) | 1991-01-04 | 1992-07-23 | Perseptive Biosystems, Inc. | Sulfonamide bonded hydrophilic coatings |
| US5155018A (en) | 1991-07-10 | 1992-10-13 | Hahnemann University | Process and kit for isolating and purifying RNA from biological sources |
| US5395498A (en) | 1991-11-06 | 1995-03-07 | Gombinsky; Moshe | Method for separating biological macromolecules and means therfor |
| US5734020A (en) | 1991-11-20 | 1998-03-31 | Cpg, Inc. | Production and use of magnetic porous inorganic materials |
| US5610274A (en) | 1991-11-20 | 1997-03-11 | Cpg, Inc. | Production and use of magnetic porous inorganic materials |
| US5346994A (en) | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
| US5316680A (en) | 1992-10-21 | 1994-05-31 | Cornell Research Foundation, Inc. | Multimodal chromatographic separation media and process for using same |
| AT398973B (de) | 1992-11-18 | 1995-02-27 | Bonn Guenther Dr | Verfahren zur trennung von nukleinsäuren |
| JP3615545B2 (ja) | 1993-02-01 | 2005-02-02 | キアゲン・エヌ・ブイ | 第四級アンモニウム塩界面活性剤及びそのｒｎａの単離剤 |
| DE4307262A1 (de) | 1993-03-02 | 1994-09-08 | Christian Bergemann | Magnetisches polymeres Siliciumdioxid |
| DE69433425T2 (de) | 1993-08-30 | 2004-10-07 | Promega Corp | Zusammensetzungen und verfahren zur reinigung von nukleinsäuren |
| DE59506355D1 (de) | 1994-02-07 | 1999-08-12 | Qiagen Gmbh | Chromatographische isolierung von nucleinsäuren |
| US5990301A (en) | 1994-02-07 | 1999-11-23 | Qiagen Gmbh | Process for the separation and purification of nucleic acids from biological sources |
| DE59505786D1 (de) | 1994-02-07 | 1999-06-02 | Qiagen Gmbh | Verfahren zur abreicherung oder entfernung von endotoxinen |
| US5582988A (en) | 1994-09-15 | 1996-12-10 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same |
| US5652348A (en) | 1994-09-23 | 1997-07-29 | Massey University | Chromatographic resins and methods for using same |
| US5654141A (en) | 1994-11-18 | 1997-08-05 | Thomas Jefferson University | Amplification based detection of bacterial infection |
| US5660984A (en) | 1994-12-09 | 1997-08-26 | Davis; Thomas E. | DNA isolating apparatus comprising a non-porous DNA binding, anion exchange resin and methods of use thereof |
| AR003122A1 (es) | 1995-05-19 | 1998-07-08 | Merck & Co Inc | Un proceso para aislacion y purificacion de plasmidos en fermentadores de gran escala y el adn aislado y purificado obtenido mediante dicho proceso. |
| DE19520398B4 (de) | 1995-06-08 | 2009-04-16 | Roche Diagnostics Gmbh | Magnetisches Pigment |
| JP2965131B2 (ja) | 1995-07-07 | 1999-10-18 | 東洋紡績株式会社 | 核酸結合用磁性担体およびそれを用いる核酸単離方法 |
| US5783686A (en) | 1995-09-15 | 1998-07-21 | Beckman Instruments, Inc. | Method for purifying nucleic acids from heterogenous mixtures |
| SE9600590D0 (sv) | 1996-02-19 | 1996-02-19 | Pharmacia Biotech Ab | Sätt för kromatografisk separation av peptider och nukleinsyra samt ny högaffin jonbytesmatris |
| JP3940935B2 (ja) | 1996-06-11 | 2007-07-04 | 東洋紡績株式会社 | プラスミドｄｎａの抽出精製方法 |
| JPH09327291A (ja) | 1996-06-11 | 1997-12-22 | Toyobo Co Ltd | Ｒｎａの抽出精製方法 |
| US6027945A (en) | 1997-01-21 | 2000-02-22 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
| CZ297990B6 (cs) | 1997-01-21 | 2007-05-16 | W. R. Grace & Co.-Conn. | Cásticový adsorbent a zpusob jeho výroby |
-
1999
- 1999-05-14 US US09/312,139 patent/US6270970B1/en not_active Expired - Fee Related
-
2000
- 2000-05-12 AT AT00930626T patent/ATE272111T1/de not_active IP Right Cessation
- 2000-05-12 JP JP2000618447A patent/JP2002543980A/ja not_active Ceased
- 2000-05-12 EP EP00930626A patent/EP1179056B1/en not_active Expired - Lifetime
- 2000-05-12 CA CA002372521A patent/CA2372521C/en not_active Expired - Fee Related
- 2000-05-12 WO PCT/US2000/012954 patent/WO2000070041A1/en not_active Ceased
- 2000-05-12 AU AU48415/00A patent/AU774810B2/en not_active Ceased
- 2000-05-12 DE DE60012506T patent/DE60012506T2/de not_active Expired - Lifetime
-
2001
- 2001-07-24 US US09/912,045 patent/US6376194B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1179056B1 (en) | 2004-07-28 |
| WO2000070041A1 (en) | 2000-11-23 |
| ATE272111T1 (de) | 2004-08-15 |
| AU774810B2 (en) | 2004-07-08 |
| US6376194B2 (en) | 2002-04-23 |
| DE60012506D1 (de) | 2004-09-02 |
| DE60012506T2 (de) | 2005-07-28 |
| US6270970B1 (en) | 2001-08-07 |
| JP2002543980A (ja) | 2002-12-24 |
| CA2372521A1 (en) | 2000-11-23 |
| AU4841500A (en) | 2000-12-05 |
| EP1179056A1 (en) | 2002-02-13 |
| US20020001812A1 (en) | 2002-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2372521C (en) | Mixed-bed solid phase and its use in the isolation of nucleic acids | |
| US6284470B1 (en) | Kits for cell concentration and lysate clearance using paramagnetic particles | |
| US6806362B2 (en) | pH dependent ion exchange matrix and method of use in the isolation of nucleic acids | |
| US6194562B1 (en) | Endotoxin reduction in nucleic acid purification | |
| DE69802191T2 (de) | Festphase nukleinsäure-isolierung | |
| JP2009118858A (ja) | 常磁性粒子を用いた集細胞及びライセート清澄化 | |
| WO2000065041A1 (en) | Process for nucleic acid purification using silicon carbide | |
| US20070031880A1 (en) | Chemical treatment of biological samples for nucleic acid extraction and kits therefor | |
| AU2002225942B2 (en) | Lysate clearance and nucleic acid isolation using silanized silica matrices | |
| EP1621618B1 (en) | Cell concentration and lysate clearance using paramagnetic particles | |
| KR20250139284A (ko) | 핵산의 분리 및/또는 정제 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |